INSERT INTO analytics_feasibility_study (
    analytics_feasibility_study_sid,
    study,
    study_title,
    alternate_study_id,
    product,
    primary_indication,
    disease,
    therapeutic_area,
    study_status,
    study_phase,
    study_type,
    protocol_approval_date,
    study_enrollment_end_date,
    planned_start_date,
    actual_start_date,
    planned_end_date,
    actual_end_date,
    sponsor,
    patient_population,
    cro_name,
    aro_name,
    operational_responsible,
    study_associate,
    study_business_administrator,
    study_manager,
    planned_sites,
    actual_sites,
    planned_country,
    actual_country,
    planned_subjects,
    last_milestone_achieved,
    next_critical_milestone,
    first_subject_enrolled_dosed_milestone_actual_date,
    first_site_activated_milestone_actual_date,
    in_ctms,
    in_etmf,
    in_ppmi,
    screened_subjects,
    enrolled_subjects,
    screening_rate_subjects_per_month,
    screening_rate_subjects_per_site_per_month,
    screening_rate_subjects_per_site_per_month_wtd_avg,
    enrollment_rate_subjects_per_month,
    enrollment_rate_subjects_per_site_per_month_wtd_avg,
    enrollment_rate_subjects_per_site_per_month,
    time_to_first_site_activation_months,
    site_activation_cycle_time_min_months,
    site_activation_cycle_time_max_months,
    site_activation_cycle_time_avg_months,
    site_activation_cycle_time_std_dev_months,
    site_activation_cycle_time_10th_percentile_months,
    site_activation_cycle_time_25th_percentile_months,
    site_activation_cycle_time_50th_percentile_months,
    site_activation_cycle_time_75th_percentile_months,
    site_activation_cycle_time_90th_percentile_months,
    enrolling_countries,
    enrolling_sites,
    first_site_activation_date,
    screening_duration_in_months,
    enrollment_duration_in_months,
    screening_planned_count_cum_cur_month,
    randomization_planned_count_cum_cur_month,
    enrollment_planned_count_cum_cur_month,
    site_activation_planned_count_cum_cur_month,
    recruitment_deviation,
    site_activation_deviation,
    etl_created_date,
    etl_updated_date
)
VALUES
(
    '1001',
    'DU176b-D-U305',
    'Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots.',
    'DSI256',
    'Edoxaban tosylate(DU-176b)',
    'pulmonary embolism',
    'pulmonary embolism',
    'Thrombosis',
    'Enrolling',
    'Phase III',
    'Interventional',
    '2021-03-25 00:00:00',
    NULL,
    '2021-03-25 00:00:00',
    '2021-05-26 00:00:00',
    '2027-11-18 00:00:00',
    NULL,
    'Daiichi Sankyo',
    'Asain, Caucasian, African',
    'IQVIA',
    NULL,
    'CRO',
    'Vivek',
    'Ashok',
    'David',
    '42',
    '36',
    '12',
    '10',
    '7500',
    'Fist Subject In',
    'Last Site activation',
    '2021-07-29 00:00:00',
    '2021-07-01 00:00:00',
    NULL,
    NULL,
    NULL,
    '3300',
    '2500',
    '18',
    '16',
    '15',
    '13',
    '12',
    '11',
    '3',
    '3',
    '6',
    '4.5',
    '4',
    '6',
    '11',
    '16',
    '18',
    '22',
    '8',
    '33',
    '2021-07-01 00:00:00',
    '-',
    '-',
    '3800',
    '4600',
    '3200',
    '42',
    '0.23',
    '0.15',
    NULL,
    NULL
),
(
    '1002',
    'DU176b-D-U306',
    'A clinical trial to study the effects of carboplatin / Paclitaxel and a new drug, CS- 7017, in patients with Non-Small Cell Lung Cancer',
    'DS2456',
    'Carboplatin IV',
    'Lung Cancer',
    'Lung Cancer',
    'Oncology',
    'Enrolling',
    'Phase III',
    'Interventional',
    '2023-03-26 00:00:00',
    NULL,
    '2022-03-26 00:00:00',
    '2022-05-27 00:00:00',
    '2025-11-19 00:00:00',
    NULL,
    'Daiichi Sankyo',
    'Asain, Caucasian, African',
    'PPD',
    NULL,
    'CRO',
    'Vivek',
    'Ashok',
    'David',
    '53',
    '12',
    '13',
    '12',
    '1500',
    '50% Subjects Enrolled',
    '75% subjects enrolled',
    '2022-07-30 00:00:00',
    '2022-07-02 00:00:00',
    NULL,
    NULL,
    NULL,
    '2392',
    '820',
    '18',
    '15',
    '14',
    '13',
    '11',
    '9',
    '2',
    '3',
    '3',
    '3.6',
    '3',
    '7',
    '13',
    '18',
    NULL,
    '24',
    '7',
    '45',
    '2022-07-02 00:00:00',
    NULL,
    NULL,
    '2900',
    '3600',
    '900',
    '51',
    '0.24',
    '0.17',
    NULL,
    NULL
),
(
    '1003',
    'DU176b-D-U307',
    'Global Study to Assess the Safety and Effectiveness of DU-176b vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation (Engage-AF TIMI-48)',
    'DS2387',
    'Drug: DU-176b tablets (high dose regimen) DU-176b tablets plus warfarin placebo tablets each taken once daily for 24 months',
    'Atrial Fibrillation (AF),',
    'Atrial Fibrillation (AF),',
    'Cardiology',
    'Enrolling',
    'Phase III',
    'Interventional',
    '2022-03-27 00:00:00',
    NULL,
    '2023-03-27 00:00:00',
    '2023-05-28 00:00:00',
    '2026-11-20 00:00:00',
    NULL,
    'Daiichi Sankyo',
    'Asain, Caucasian, African',
    'IQVIA',
    NULL,
    'CRO',
    'Vivek',
    'Ashok',
    'David',
    '40',
    '38',
    '15',
    '13',
    '3000',
    '25% Subjects Enrolled',
    '50% Subjects Enrolled',
    '2023-07-31 00:00:00',
    '2023-07-03 00:00:00',
    NULL,
    NULL,
    NULL,
    '1789',
    '1200',
    '18',
    '15',
    '12',
    '13',
    '13',
    '11',
    '3',
    '6',
    '3',
    '3.6',
    '3',
    '12',
    '18',
    NULL,
    NULL,
    '22',
    '10',
    '39',
    '2023-07-03 00:00:00',
    NULL,
    NULL,
    '4500',
    '5500',
    '1500',
    '46',
    '0.18',
    '0.21',
    NULL,
    NULL
);
